Terms: = Bone cancer AND FIP1L1, DKFZp586K0717, 81608, ENSG00000145216, Q6UN15
32 results:
1. fip1l1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report.
Ali S; Al-Qattan Y; Awny W; Hamadah A; Pinto K; AlShemmari S
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1769. PubMed ID: 36517458
[TBL] [Abstract] [Full Text] [Related]
2. EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.
Leguit RJ; Orazi A; Kucine N; Kvasnicka HM; Gianelli U; Arber DA; Porwit A; Ponzoni M
Virchows Arch; 2022 Oct; 481(4):621-646. PubMed ID: 35819517
[TBL] [Abstract] [Full Text] [Related]
3. LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia.
Ma G; Gezer D; Herrmann O; Feldberg K; Schemionek M; Jawhar M; Reiter A; Brümmendorf TH; Koschmieder S; Chatain N
Mol Carcinog; 2020 Jan; 59(1):87-103. PubMed ID: 31691359
[TBL] [Abstract] [Full Text] [Related]
4. Identification of a novel PDGFRA point mutation at p.P6L as a potential molecular target of imatinib in an eosinophilia patient showing genetic heterogeneity.
Zhao M; Wu Q; Xia L; Zhang M; Yang J; Li Y; Tu S; Wang Y
Cancer Biol Ther; 2019; 20(4):402-407. PubMed ID: 30359545
[TBL] [Abstract] [Full Text] [Related]
5. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
[TBL] [Abstract] [Full Text] [Related]
6. Myeloid neoplasm with eosinophilia associated with isolated extramedullary fip1l1/PDGFRA rearrangement.
Hilal T; Fauble V; Ketterling RP; Kelemen K
Cancer Genet; 2018 Jan; 220():13-18. PubMed ID: 29310833
[TBL] [Abstract] [Full Text] [Related]
7. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract] [Full Text] [Related]
8. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.
Khoury P; Desmond R; Pabon A; Holland-Thomas N; Ware JM; Arthur DC; Kurlander R; Fay MP; Maric I; Klion AD
Allergy; 2016 Jun; 71(6):803-10. PubMed ID: 26797802
[TBL] [Abstract] [Full Text] [Related]
9. Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation.
Schwaab J; Jawhar M; Naumann N; Schmitt-Graeff A; Fabarius A; Horny HP; Cross NC; Hofmann WK; Reiter A; Metzgeroth G
Ann Hematol; 2016 Mar; 95(4):557-62. PubMed ID: 26797429
[TBL] [Abstract] [Full Text] [Related]
10. Therapy-related acute myeloid leukemia with eosinophilia, basophilia, t(4;14)(q12;q24) and PDGFRA rearrangement: a case report and review of the literature.
Zhou J; Papenhausen P; Shao H
Int J Clin Exp Pathol; 2015; 8(5):5812-20. PubMed ID: 26191303
[TBL] [Abstract] [Full Text] [Related]
11. WATERSHED INFARCTION IN HYPEREOSINOPHILIC SYNDROME: A DIAGNOSTIC DILEMMA IN fip1l1-PDGFR ALPHA-ASSOCIATED MYELOID NEOPLASM.
Marton I; Pósfai É; Annus JK; Borbényi Z; Nemes A; Vecsei L; Vörös E
Ideggyogy Sz; 2015 May; 68(5-6):212-6. PubMed ID: 26182612
[TBL] [Abstract] [Full Text] [Related]
12. F604S exchange in fip1l1-PDGFRA enhances fip1l1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.
Gorantla SP; Zirlik K; Reiter A; Yu C; Illert AL; Von Bubnoff N; Duyster J
Leukemia; 2015 Aug; 29(8):1763-70. PubMed ID: 25761934
[TBL] [Abstract] [Full Text] [Related]
13. Discovery of imatinib-responsive fip1l1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.
Shah S; Loghavi S; Garcia-Manero G; Khoury JD
J Hematol Oncol; 2014 Mar; 7():26. PubMed ID: 24669761
[TBL] [Abstract] [Full Text] [Related]
14. Hes1 upregulation contributes to the development of fip1l1-PDGRA-positive leukemia in blast crisis.
Uchida T; Kitaura J; Nakahara F; Togami K; Inoue D; Maehara A; Nishimura K; Kawabata KC; Doki N; Kakihana K; Yoshioka K; Izawa K; Oki T; Sada A; Harada Y; Ohashi K; Katayama Y; Matsui T; Harada H; Kitamura T
Exp Hematol; 2014 May; 42(5):369-379.e3. PubMed ID: 24486648
[TBL] [Abstract] [Full Text] [Related]
15. Complete and long-lasting cytologic and molecular remission of fip1l1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
[TBL] [Abstract] [Full Text] [Related]
16. [The hematological malignancies related to primary hypereosinophilia and their diagnostics].
Skonieczka K; Matiakowska K; Haus O
Postepy Hig Med Dosw (Online); 2014 Dec; 68():1530-7. PubMed ID: 25834096
[TBL] [Abstract] [Full Text] [Related]
17. fip1l1-PDGFRα-positive hypereosinophilic syndrome in childhood: a case report and review of literature.
Farruggia P; Giugliano E; Russo D; Trizzino A; Lorenzatti R; Santoro A; D'Angelo P
J Pediatr Hematol Oncol; 2014 Jan; 36(1):e28-30. PubMed ID: 23337549
[TBL] [Abstract] [Full Text] [Related]
18. A case of nonleukemic myeloid sarcoma with fip1l1-PDGFRA rearrangement: an unusual presentation of a rare disease.
Chen D; Bachanova V; Ketterling RP; Begna KH; Hanson CA; Viswanatha DS
Am J Surg Pathol; 2013 Jan; 37(1):147-51. PubMed ID: 23232855
[TBL] [Abstract] [Full Text] [Related]
19. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
[TBL] [Abstract] [Full Text] [Related]
20. [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].
Hussein K; Büsche G; Schlue J; Lehmann U; Kreipe H
Pathologe; 2012 Nov; 33(6):508-17. PubMed ID: 23085694
[TBL] [Abstract] [Full Text] [Related]
[Next]
